QQX
- 产品代码
- QQX
- 器械名称
- Respiratory Specimen Nucleic Acid Sars-Cov-2 Test
- 管理类别
- 第 2 类(Class II)
- 21 CFR 条款
- 21 CFR 866.3981
- FDA 专业组
- Microbiology
- 上市路径
- 需提交 510(k) 上市前通告
- 该代码近三年的 510(k)
- 6 件
- 其中 Summary 已存档
- 6 份,可直接下载
- FDA 历史累计 510(k)
- 11 件(全部年份;本站只收录近三年的明细)
FDA 分类定义
A device to detect and identify nucleic acid targets in respiratory specimens from SARS-CoV-2 that cause COVID-19 is an in vitro diagnostic device intended for the detection and identification of SARS-CoV-2 nucleic acid targets in human clinical respiratory specimens from patients suspected of COVID-19 based on signs and symptoms of respiratory infections by their healthcare providers. The device is intended to aid in the diagnosis of COVID-19 in conjunction with other clinical, epidemiologic, and laboratory data or other risk factors.
该代码近三年的 510(k)(6 件)
| 510(k) 号 | 批准日期 | 申请人 | 器械名称 | 摘要 |
|---|---|---|---|---|
| K243396 | 2025-02-13 | Hologic, Inc. | Aptima SARS-CoV-2 Assay | |
| K240867 | 2025-02-11 | Roche Molecular Systems, Inc. | cobas® SARS-CoV-2 Qualitative for use on the cobas® … | |
| K242109 | 2025-01-15 | Cepheid® | Xpert® Xpress CoV-2 plus (XPRS-COV2-10) | |
| K241580 | 2024-12-06 | Abbott Molecular | Alinity m SARS-CoV-2 AMP Kit (09N78-096); Alinity m … | |
| K233453 | 2024-07-10 | Life Technologies Corporation | Applied Biosystems TaqPath COVID-19 Diagnostic PC… | |
| K230440 | 2023-10-13 | Cepheid® | Xpert® Xpress CoV-2 plus |
FDA 官方分类页: QQX
分类与上市路径以 FDA 现行公告为准。本页数据来自 openFDA(CC0 公有领域),不构成注册策略建议。